Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MAP2 | P11137 | 3/20 | 0.56 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.56 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162859 | 0.87 | PTGS2 (0.54) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL27464080 | 0.85 | PADI4 (0.68) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3091466 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5203951 | 0.83 | KDM4E (0.96) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL6857725 | 0.83 | HPGD (0.62) | KDM4EALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL6857639 | 0.83 | PTGS2 (0.50) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL9816507 | 0.81 | KDM4E (0.79) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL9441674 | 0.81 | KDM4E (0.79) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL4591604 | 0.81 | KDM4E (0.54) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL18919757 | 0.80 | MCL1 (0.75) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | claimed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | claimed |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | disclosed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | IDO1, IDO2, INMT | KDM4E 512/4885ALDH1A1 788/4885HPGD 253/4885 |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | IDO1, IDO2, INMT | KDM4E 902/4885ALDH1A1 1731/4885HPGD 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.